Business Insights

Fuisz Pharma LLC Receives a Patent for a Non-Invasive Urological Device to Treat Benign Prostate Hyperplasia Symptoms (BPH)

Fuisz Pharma
The first patent for Fuisz Pharma LLC's non-invasive urological device platform to alleviate symptoms of BPH, US 11,213,41, entitled "Device and Method for Reducing Urinary Retention," was issued via Fuisz LLC. Fuisz Pharma LLC is still looking for additional patent protection to go along with the one that was obtained.

The Fuisz device is non-invasive, simple to use, and has been shown to help initiate urination, minimize dribbling and nocturia, and decrease urine retention, all of which are frequent symptoms of BPH. The gadget can be used for easy and fast double voids.

The Fuisz device works on the principle of using a cool, rapidly transferred thermal transfer to induce the start of urination. Urination stream pressure requirements are dropped simultaneously.

The Fuisz gadget isn't intended to replace existing pharmaceutical or surgical treatments. It is meant to be used as an auxiliary non-invasive therapy to address symptoms.

Millions of American men suffer from urinary symptoms associated with BPH. These symptoms raise serious quality of life issues for patients. No male wishes to pause at a bathroom stall to initiate urination; be fearful of urgency during a trip to the store; or be deprived of a restful night by nocturia.”

Joseph Fuisz, the Managing Member of Fuisz Pharma

“The non-invasive Fuisz device offers substantial benefits for patients with BPH-type symptoms.”

“We are preparing to seek approval for the Fuisz device as a medical device.”

Spotlight

Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More